Syncona backs spectrometry play OMass in £14M round

Making the switch to drug development from consulting services, OMass Therapeutics Ltd. (Oxford, U.K.) relaunched on Wednesday with a £14 million ($18 million) series A round led by new investor Syncona Ltd. (LSE:SYNC) alongside Oxford Sciences Innovation.

In Syncona's latest earnings report, also released Wednesday, the investor disclosed that it contributed £9.8 million to the round in June, giving it a 46% stake in OMass...